BR Biopharma (NASDAQ:BRBI) and Cherry Hill Mortgage Investment (NYSE:CHMI) Head to Head Survey

Cherry Hill Mortgage Investment (NYSE:CHMI – Get Free Report) and BR Biopharma (NASDAQ:BRBI – Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cherry Hill Mortgage Investment and BR Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cherry Hill Mortgage Investment 1 2 1 0 2.00
BR Biopharma 1 1 0 0 1.50

Cherry Hill Mortgage Investment currently has a consensus price target of $3.00, suggesting a potential upside of 35.44%. Given Cherry Hill Mortgage Investment’s stronger consensus rating and higher possible upside, research analysts plainly believe Cherry Hill Mortgage Investment is more favorable than BR Biopharma.

Risk and Volatility

Cherry Hill Mortgage Investment has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, BR Biopharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cherry Hill Mortgage Investment and BR Biopharma”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cherry Hill Mortgage Investment $61.10 million 1.34 $6.83 million $0.02 110.75
BR Biopharma $2.23 billion 0.04 $31.36 million $0.08 99.58

BR Biopharma has higher revenue and earnings than Cherry Hill Mortgage Investment. BR Biopharma is trading at a lower price-to-earnings ratio than Cherry Hill Mortgage Investment, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cherry Hill Mortgage Investment and BR Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cherry Hill Mortgage Investment 17.18% 24.21% 2.03%
BR Biopharma N/A N/A N/A

Dividends

Cherry Hill Mortgage Investment pays an annual dividend of $0.40 per share and has a dividend yield of 18.1%. BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 5.3%. Cherry Hill Mortgage Investment pays out 2,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Cherry Hill Mortgage Investment has increased its dividend for 1 consecutive years. Cherry Hill Mortgage Investment is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

18.5% of Cherry Hill Mortgage Investment shares are owned by institutional investors. 1.6% of Cherry Hill Mortgage Investment shares are owned by company insiders. Comparatively, 29.4% of BR Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cherry Hill Mortgage Investment beats BR Biopharma on 12 of the 17 factors compared between the two stocks.

About Cherry Hill Mortgage Investment

(Get Free Report)

Cherry Hill Mortgage Investment Corporation is a real estate investment trust focused on residential mortgage-related assets in the United States. The company began operations in 2013 and invests in assets tied to the U.S. housing and mortgage markets. Its portfolio has included agency and non-agency residential mortgage-backed securities, mortgage servicing rights and related servicing assets, as well as residential mortgage loans. These investments expose the company to income from mortgage payments and mortgage servicing activities.

About BR Biopharma

(Get Free Report)

Brii Biosciences Limited is a biotechnology company focused on developing treatments for infectious diseases and other conditions with significant unmet medical needs. Founded in 2017, the company has operated in the United States and China. Its research has included investigational therapies for chronic hepatitis B and other viral diseases, as well as drug-resistant bacterial infections. The company’s development programs have included BRII-179, a therapeutic vaccine candidate for hepatitis B, and BRII-835, an investigational RNA-based therapy.

Receive News & Ratings for Cherry Hill Mortgage Investment Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cherry Hill Mortgage Investment and related companies with MarketBeat.com's FREE daily email newsletter.